相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Sipuleucel-T: A vaccine for metastatic, asymptomatic, androgen-independent prostate cancer
Punam H. Patel et al.
ANNALS OF PHARMACOTHERAPY (2008)
Human Flt-3 ligand-mobilized dendritic cells, require additional activation to drive effective immune responses
Kerrilyn R. Diener et al.
EXPERIMENTAL HEMATOLOGY (2008)
Dendritic cells program non-immunogenic prostate-specific T cell responses beginning at early stages of prostate tumorigenesis
Marianne A. Mihalyo et al.
PROSTATE (2007)
Tolerization of tumor-specific T cells despite efficient initial priming in a primary murine model of prostate cancer
Michael J. Anderson et al.
JOURNAL OF IMMUNOLOGY (2007)
Advances in prostate cancer immunotherapies
Michael Basler et al.
DRUGS & AGING (2007)
Interferons, immunity and cancer immunoediting
Gavin P. Dunn et al.
NATURE REVIEWS IMMUNOLOGY (2006)
Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer
Eric J. Small et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
T-cell recognition of a prostate specific antigen is not sufficient to induce prostate tissue destruction
JR Lees et al.
PROSTATE (2006)
Infiltration of tumor-reactive transforming growth factor-beta insensitive CD8+ T cells into the tumor parenchyma is associated with apoptosis and rejection of tumor cells
Q Zhang et al.
PROSTATE (2006)
Deletion is neither sufficient nor necessary for the induction of peripheral tolerance in mature CD8+ T cells
JR Lees et al.
IMMUNOLOGY (2006)
TGF-β maintains dormancy of prostatic stem cells in the proximal region of ducts
SN Salm et al.
JOURNAL OF CELL BIOLOGY (2005)
Technology Insight: vaccine therapy for prostate cancer
J Vieweg et al.
NATURE CLINICAL PRACTICE UROLOGY (2005)
Peripheral T cell tolerance occurs early during spontaneous prostate cancer development and can be rescued by dendritic cell immunization
E Degl'Innocenti et al.
EUROPEAN JOURNAL OF IMMUNOLOGY (2005)
Association of pre- and postoperative plasma levels of transforming growth factor β1 and interleukin 6 and its soluble receptor with prostate cancer progression
SF Shariat et al.
CLINICAL CANCER RESEARCH (2004)
Tumour escape: antitumour effectors too much of a good thing?
G Pawelec
CANCER IMMUNOLOGY IMMUNOTHERAPY (2004)
Escape from immunotherapy: possible mechanisms that influence tumor regression/progression
M Ahmad et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2004)
Specific abrogation of transforming growth factor-β signaling in T cells alters atherosclerotic lesion size and composition in mice
A Gojova et al.
BLOOD (2003)
Immune-mediated eradication of tumors through the blockade of transforming growth factor-β signaling in T cells
L Gorelik et al.
NATURE MEDICINE (2001)
Down-regulation of TGF-β1 production restores immunogenicity in prostate cancer cells
E. Matthews et al.
BRITISH JOURNAL OF CANCER (2000)
Disruption of T cell homeostasis in mice expressing a T cell-specific dominant negative transforming growth factor β II receptor
PJ Lucas et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2000)
Abrogation of TGFβ signaling in T cells leads to spontaneous T cell differentiation and autoimmune disease
L Gorelik et al.
IMMUNITY (2000)
分享论文
